Heikki Joensuu

Research interests

Publications

• Author Correction: FinnGen provides genetic insights from a well-phenotyped isolated population

  Nature · 2023 · https://doi.org/10.1038/s41586-023-05837-8

• FinnGen provides genetic insights from a well-phenotyped isolated population

  Nature · 2023 · https://doi.org/10.1038/s41586-022-05473-8

• FinnGen: Unique genetic insights from combining isolated population and national health register data

  medRxiv · 2022 · https://doi.org/10.1101/2022.03.03.22271360

• Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00288-6

• Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.005

• Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.07.006

• Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.01010

• Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · 10.1093/annonc/mdy095

• Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · 10.1093/annonc/mdy310

• Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy096

• Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00373-3

• KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.57.4970

• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

  Annals of Oncology · 2014 · 10.1093/annonc/mdu112

• Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)61857-1

• Comparison of solution-based exome capture methods for next generation sequencing

  Genome biology · 2011 · https://doi.org/10.1186/gb-2011-12-9-r94

• Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70299-6

• Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

  Genes Chromosomes and Cancer · 2010 · https://doi.org/10.1002/gcc.20815

• NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

  Journal of the National Comprehensive Cancer Network · 2007 · 10.6004/jnccn.2007.2002

• Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

  Annals of Oncology · 2005 · 10.1093/annonc/mdi127

• Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

  Journal of Clinical Oncology · 2003 · https://doi.org/10.1200/jco.2003.04.190

• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

  New England Journal of Medicine · 2002 · https://doi.org/10.1056/nejmoa020461

• Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

  New England Journal of Medicine · 2001 · https://doi.org/10.1056/nejm200104053441404

Current projects

No projects listed.